IP Library Granted Patent US 7,449,181
Granted Patent B2
US 7,449,181 · App. 10/333,978 · Granted Nov 11, 2008

Remedies for cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,449,181
App. No.
10/333,978
Granted
Nov 11, 2008
Kind
B2
Abstract

A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.

Claims (6)

1. A method of treating breast cancer, which is a breast cancer in which HER2 is highly expressed, comprising administering an effective amount of trastuzumab and an effective amount of amrubicin or a pharmaceutically acceptable salt thereof in combination, whereby said breast cancer is treated.

2. The method according to claim 1 , comprising administering amrubicin or a pharmaceutically acceptable salt thereof at 0.5–3.0 mg/kg/day while administering trastuzumab at 0.1–4.5 mg/kg/day.

3. The method according to claim 2 , comprising administering amrubicin or a pharmaceutically acceptable salt thereof on successive three days in every three weeks, while administering trastuzumab every one week.

4. The method according to claim 1 , comprising administering amrubicin or a pharmaceutically acceptable salt thereof at 1.5–9.0 mg/kg/day while administering trastuzumab at 0.1–4.5 mg/kg/day.

5. The method according to claim 4 , comprising administering amrubicin or a pharmaceutically acceptable salt thereof every three weeks, while administering trastuzumab every one week.

6. The method according to any one of claims 1 and 2 to 5 , wherein a dosage ratio of amrubicin or a pharmaceutically acceptable salt thereof and trastuzumab is 2:1–8:1 at one week after initiating the administration of both agents.

Assignments (2)
MERGER Recorded Dec 16, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LTD.
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017089/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2003
From: NOGUCHI, TOSHIHIRO; BABA, AKEMI; HANADA, MITSUHARU
To: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
Reel/Frame 013980/0100 →